MiR‑181a functions as an oncogene by regulating CCND1 in multiple myeloma

Yan,Xiao; Gao,Minjie; Zhang,Ping; Ouyang,Guifang; Mu,Qitian; Xu,Kaihong

doi:10.3892/ol.2020.11579

MiR‑181a functions as an oncogene by regulating CCND1 in multiple myeloma

Authors:
- Xiao Yan
- Minjie Gao
- Ping Zhang
- Guifang Ouyang
- Qitian Mu
- Kaihong Xu
View Affiliations

Affiliations: Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China, Stem Cell Laboratory, Ningbo First Hospital, Ningbo, Zhejiang 315010, P.R. China
Published online on: April 28, 2020 https://doi.org/10.3892/ol.2020.11579
Pages: 758-764
Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA-181a (miR-181a) has been demonstrated to be upregulated in patients with multiple myeloma (MM). In several studies, miR‑181a has been demonstrated to be significantly overexpressed in MM; however, its potential role in development and progression of MM remains unknown. In the present study, the functions of miR‑181a and the potential underlying molecular mechanisms in the pathogenesis of MM were examined. Increased expression of miR‑181a was observed in bone marrow samples from patients with MM and the MM RPMI8226 cell line. The role of miR‑181a was examined and it was demonstrated that it participated in the proliferation and migration processes of the MM cell line. Furthermore, it was demonstrated that the downregulation of miR‑181a inhibited the expression of CCND1, a cell cycle regulatory gene, and caused cell cycle arrest in MM cells. The results of the present study suggested that miR‑181a functions as an onco‑miRNA in MM, which serves regulatory roles by upregulating expression of CCND1 and may therefore serve as a potential target in patients with MM.

View Figures

View References

1	Kyle R and Rajkumar SV: Multiple myeloma. Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA. Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar
3	Rastgoo N, Abdi J, Hou J and Chang H: Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. J Hematol Oncol. 10:1212017. View Article : Google Scholar : PubMed/NCBI
4	Dupéré-Richer D and Licht JD: Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Curr Opin Hematol. 24:336–344. 2017. View Article : Google Scholar : PubMed/NCBI
5	Dimopoulos K, Gimsing P and Grønbæk K: The role of epigenetics in the biology of multiple myeloma. Blood Cancer J. 4:e2072014. View Article : Google Scholar : PubMed/NCBI
6	He L and Hannon GJ: Erratum: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
7	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
8	Garzon R, Fabbri M, Cimmino A, Calin GA and Croce CM: MicroRNA expression and function in cancer. Trends Mol Med. 12:580–587. 2006. View Article : Google Scholar : PubMed/NCBI
9	Kuehbacher A, Urbich C and Dimmeler S: Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci. 29:12–15. 2008. View Article : Google Scholar : PubMed/NCBI
10	Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, et al: MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 105:12885–12890. 2008. View Article : Google Scholar : PubMed/NCBI
11	Abdi J, Jian H and Chang H: Role of micro-RNAs in drug resistance of multiple myeloma. Oncotarget. 7:60723–60735. 2016. View Article : Google Scholar : PubMed/NCBI
12	de Yébenes VG, Bartolomé-Izquierdo N and Ramiro AR: Regulation of B cell development and function by microRNAs. Immunol Rev. 253:25–39. 2013. View Article : Google Scholar : PubMed/NCBI
13	Peng J, Thakur A, Zhang S, Dong Y, Wang X, Yuan R, Zhang K and Guo X: Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma. Tumour Biol. 36:8545–8552. 2015. View Article : Google Scholar : PubMed/NCBI
14	Liu N, Yang J, Yuan R, Peng J, Liu L and Guo X: Effects of miR-181a on the biological function of multiple myeloma. Oncol Rep. 42:291–300. 2019.PubMed/NCBI
15	Cao Y, Zhao D, Li P, Wang L, Qiao B, Qin X, Li L and Wang Y: MicroRNA-181a-5p impedes IL-17-induced non-small cell lung cancer proliferation and migration through targeting VCAM-1. Cell Physiol Biochem. 42:346–356. 2017. View Article : Google Scholar : PubMed/NCBI
16	Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
19	Bi C and Chng WJ: MicroRNA: Important player in the pathobiology of multiple myeloma. Biomed Res Int. 2014:5215862014. View Article : Google Scholar : PubMed/NCBI
20	Huang S, Wu S, Ding J, Lin J, Wei L, Gu J and He X: MicroRNA-181a modulates gene expression of zinc finger family members by directly targeting their coding regions. Nucleic Acids Res. 38:7211–7218. 2010. View Article : Google Scholar : PubMed/NCBI
21	Li L, Xu QH, Dong YH, Li GX, Yang L, Wang LW and Li HY: MiR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells. Eur Rev Med Pharmacol Sci. 20:2004–2010. 2016.PubMed/NCBI
22	Ghorbani S, Talebi F, Chan WF, Masoumi F, Vojgani M, Power C and Noorbakhsh F: MicroRNA-181 variants regulate T cell phenotype in the context of autoimmune neuroinflammation. Front. Immunol. 8:7582017.
23	Verduci L, Azzalin G, Gioiosa S, Carissimi C, Laudadio I, Fulci V and Macino G: microRNA-181a enhances cell proliferation in acute lymphoblastic leukemia by targeting EGR1. Leuk Res. 39:479–485. 2015. View Article : Google Scholar : PubMed/NCBI
24	Yyusnita, Norsiah, Zakiah I, Chang KM, Purushotaman VS, Zubaidah Z and Jamal R: MicroRNA (miRNA) expression profiling of peripheral blood samples in multiple myeloma patients using microarray. Malaysian J Pathol. 34:133–143. 2012.
25	Li Y, Li D, Yan Z, Qi K, Chen L, Zjang Z, Fan G, Li H, Xu K and Li Z: Potential relationship and clinical significance of miRNAs and Th17 cytokines in patients with multiple myeloma. Leuk Res. 38:1130–1135. 2014. View Article : Google Scholar : PubMed/NCBI
26	Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, et al: Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res. 19:3130–3142. 2013. View Article : Google Scholar : PubMed/NCBI
27	Baldin V, Lukas J, Marcote MJ, Pagano M and Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
28	Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C and Pestell RG: Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: Past and present. Expert Opin Investig Drugs. 23:295–304. 2014. View Article : Google Scholar : PubMed/NCBI
29	Lesage D, Troussard X and Sola B: The enigmatic role of cyclin D1 in multiple myeloma. Int J Cancer. 115:171–176. 2005. View Article : Google Scholar : PubMed/NCBI
30	Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M Jr, Jungkamp AC, Munschauer M, et al: Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell. 141:129–141. 2010. View Article : Google Scholar : PubMed/NCBI
31	Balakrishnan I, Yang X, Brown J, Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR and Pillai MM: Genome-wide analysis of miRNA-mRNA interactions in marrow stromal cells. Stem Cells. 32:662–673. 2014. View Article : Google Scholar : PubMed/NCBI
32	Farazi TA, Ten Hoeve JJ, Brown M, Mihailovic A, Horlings HM, van de Vijver MJ, Tuschl T and Wessels LF: Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. Genome Biol. 15:R92014. View Article : Google Scholar : PubMed/NCBI